From Presentations to Roundtable Discussions and Interviews, It Was Hard to Miss BioCentriq at ISCT Paris 2023 

If you attended this year’s jam-packed ISCT annual event in Paris, there’s a good chance you came across one of our five team members during the four-day meeting. As a CDMO specializing in cell therapy manufacturing, BioCentriq was eager to participate in this event focused on cell and gene therapy translation, which takes an integrative approach across all stakeholders to tackle key topics ranging from translational research and preclinical development through clinical trials, regulatory approvals, commercialization, and the ultimate goal of patient access.  

BioCentriq had five team members attend ISCT, including CEO Haro Hartounian, Ph.D., VP of Development David Smith, Ph.D., VP of Business Strategy and Innovation Alex Klarer, Senior Director of Business Development Chathuranga De Silva, Ph.D., and Principal NK Cell Scientist Pankaj Mishra, Ph.D. 

Check out all the things our team members were up to at ISCT. 

CEO Gives Presentation and Unveils LEAP™ Advanced Therapy Platform 

Dr. Hartounian gave his presentation, Setting the Stage for Successful Clinical Manufacturing of Cell & Gene Therapies, in the Global Showcase Theater, revealing how BioCentriq, as a collaborative CDMO with expertise in cell therapy manufacturing, can help bring novel drug therapies to market. One of the ways in which BioCentriq is equipped to do this is through the new LEAP™ Advanced Therapy Platform, which Dr. Hartounian unveiled for the first time during his presentation. 

The LEAP™ Platform empowers early-stage biotech companies to prioritize speed by leveraging existing BioCentriq assets, including master batch records, established SOPs, qualified analytical methods, equipment and facilities, trained personnel, completed aseptic validation, and more. This results in reduced timelines, de-risked trials, and getting to patients faster. With the LEAP™ timeline, therapy developers can get to engineering runs in as little as six months. 

Click here to download our LEAP™ Platform overview.  

Research Poster Presented on Abstract: Large-scale biomanufacturing platform to produce high-quality, therapeutically relevant NK cells using the LEAP-NK™ Platform 

This research poster was presented during the poster hall by Principal NK Cell Scientist Dr. Pankaj Mishra. It drew many curious attendees with its data displaying the efficacy of BioCentriq’s new LEAP™ Platform. The results of the study suggest that BioCentriq’s LEAP-NK™ platform utilizing propriety feeder cell lines can enhance expansion of NK cells >12,000 fold. 

Click here to download the research poster. 

VPs Participate in Roundtable Discussions & Corporate Session  

VP of Business Strategy and Innovation Alex Klarer was a panelist during the Terumo Blood Cell and Technologies Corporate Session, Streamlining process optimization from process development to commercial with automated solutions. He and his fellow panelists explored if — with an increasing number of technologies coming to market to help automate processes — we are truly ready to set industry standards, or if it is wiser to focus on setting guidelines. 

Dr. David Smith, VP of Development, lent his expertise to lively roundtable discussions. The first was Manufacturing Gene-Modified Cells: How Do we Get the Process Right? wherein the panelists explored innovative process development strategies that will improve the manufacturing environment. The second discussion was Thinking Outside the Box: How Can we Redefine Manufacturing? The panelists discussed transforming manufacturing from a cost center into a key capability enabling innovation. 

CEO Gives ISCT TV Interview — Watch Now! 

During an ISCT TV Interview, Dr. Haro Hartounian gave a condensed version of his initial presentation (detailed above) unveiling the LEAP™ Advanced Therapy Platform and discussing BioCentriq’s ability to set the stage for successful clinical manufacturing. You can watch it now! 

Meeting Industry Colleagues at the BioCentriq Booth 

It was wonderful for our team to host a booth and engage with so many attendees. We also had the opportunity to meet with people one-on-one, which is exactly what our Senior Director of Business Development, Dr. Chat De Silva, was doing throughout the week.  

If you’re interested in collaborating with BioCentriq to bring your novel drug therapy to market and would like to learn about our capabilities, including process development and manufacturing, our team is always available to meet with you. 

Click here to contact us today.